Cannabidiol (CBD): What the Evidence Supports, and What It Does Not

Cannabidiol (CBD) is a cannabis compound that generally does not produce the intoxicating “high” associated with Δ9-tetrahydrocannabinol (THC). Its popularity has grown faster than the clinical evidence, however. CBD is being marketed for pain, anxiety, inflammation, sleep problems, and neurological disorders, but research does not support treating all of these uses as equally established.

The clearest evidence is for a purified, prescription CBD medicine used for specific seizure disorders. Evidence for anxiety and chronic pain is more limited, while claims involving arthritis, inflammatory disease, Alzheimer’s disease, and Parkinson’s disease remain largely preliminary.

How CBD may act in the body

The endocannabinoid system helps regulate processes including pain signaling, mood, immune activity, appetite, and sleep. It includes cannabinoid receptors such as CB1 and CB2, naturally occurring endocannabinoids, and enzymes that produce and break down those compounds.

Unlike THC, CBD does not act as a strong direct activator of CB1 receptors. Researchers have proposed that it influences several signaling systems, including serotonin, transient receptor potential, and endocannabinoid pathways. Laboratory findings also suggest possible effects on inflammation and pain processing. These mechanisms are useful for guiding research, but they do not by themselves prove that a CBD product will treat a particular disease.

Where clinical evidence is strongest

Seizure disorders

CBD’s best-established medical use is the prescription drug Epidiolex, which contains purified cannabidiol. The U.S. Food and Drug Administration has approved it for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients at least 1 year old. The approvals were based on randomized clinical trials of a standardized product—not on evidence from ordinary retail CBD oils, gummies, or creams.

Epidiolex is used under medical supervision because its prescribing information calls for liver-function testing and warns about sedation, drug interactions, and dose-related liver injury. Its dosage is weight-based and differs substantially from the informal dosing advice often given for over-the-counter products. The FDA’s prescribing information for Epidiolex provides the approved indications, dosing instructions, and safety warnings.

Anxiety

CBD may have anxiety-reducing effects, but the human evidence remains early. In a 2011 randomized study of 24 people with social anxiety disorder, a single dose of CBD reduced anxiety during a simulated public-speaking test compared with placebo. That experiment supports further research; it does not establish CBD as a proven treatment for generalized anxiety disorder, post-traumatic stress disorder, or other mood conditions.

The study also examined an acute, laboratory-based situation rather than long-term treatment. Larger and longer clinical trials are needed before CBD can be recommended as a substitute for established psychological or medical care. The original trial is available in Neuropsychopharmacology.

Chronic pain

Research on cannabinoids and chronic pain has produced mixed results, and it is important to distinguish CBD from cannabis products containing THC or combinations of THC and CBD. Many clinical trials have evaluated mixed cannabinoid preparations rather than purified CBD alone.

A 2020 meta-analysis of randomized trials found that cannabinoids produced a statistically significant but small reduction in chronic non-cancer pain. The authors rated the evidence as low to moderate and noted that non-serious side effects were more common with cannabinoids than with placebo. A separate review found inconsistent results across randomized trials, with possible modest benefits mainly in some neuropathic pain conditions.

These findings do not justify describing CBD as an established alternative to opioids or as a treatment for arthritis, multiple sclerosis, or back pain. People with persistent pain should receive an evaluation for the underlying cause and discuss evidence-based treatment options with a clinician. The 2020 pain meta-analysis can be read through PubMed, while the National Center for Complementary and Integrative Health’s evidence summary provides additional context.

Uses that remain investigational

CBD has shown anti-inflammatory, antioxidant, and neuroprotective effects in cell and animal studies. Those findings have prompted research into inflammatory bowel disease, rheumatoid arthritis, Alzheimer’s disease, Parkinson’s disease, and other conditions. They should not be confused with evidence that CBD prevents or treats these diseases in people.

At present, preclinical findings are not a sufficient basis for replacing disease-modifying treatment, neurological care, or other established therapies with CBD. Products marketed for these conditions may make claims that have not been tested in well-controlled human trials.

Safety, interactions, and product quality

CBD is not risk-free. Reported effects include sleepiness, diarrhea, reduced appetite, changes in mood, and fatigue. At prescription doses, it can cause elevations in liver enzymes or clinically important liver injury. CBD can also affect how other medicines are metabolized, making medication interactions a particular concern for people taking antiseizure drugs, sedatives, blood thinners, or medicines that can affect the liver.

Retail products add another uncertainty: their contents may not match the label. Testing has found products with inaccurate CBD concentrations and, in some cases, THC or contaminants such as pesticides, heavy metals, bacteria, or fungi. The Centers for Disease Control and Prevention’s CBD guidance notes that safety data remain limited and that CBD may interact with medicines.

People who are pregnant or breastfeeding, those with liver disease, and anyone taking prescription medication should consult a healthcare professional before using CBD. CBD should also be kept away from children and pets.

Dosage and legal considerations

There is no universally established dose for over-the-counter CBD products, and absorption varies by formulation, product quality, food intake, and individual metabolism. A dose used in a clinical trial or in Epidiolex should not be transferred to a commercial tincture or edible without medical guidance. Starting or changing CBD treatment is especially inappropriate without supervision when it is being used alongside other medicines.

In the United States, the 2018 Farm Bill removed hemp—defined federally as cannabis containing no more than 0.3% THC by dry weight—from the federal Controlled Substances Act. That change did not make every CBD product an FDA-approved medicine or automatically authorize CBD in foods, dietary supplements, or therapeutic products. Federal and state rules can differ, and the FDA continues to warn that most CBD products have not been evaluated for safety or effectiveness for their advertised uses. Its consumer guidance on cannabis-derived products and CBD explains these distinctions.

CBD is therefore best understood as a compound with one well-supported prescription use and several promising but unproven applications. The strongest evidence concerns purified CBD for particular severe seizure disorders. For pain, anxiety, inflammation, and neurodegenerative disease, the evidence is more limited, product-specific, and uncertain. Anyone considering CBD should discuss the potential benefits, risks, interactions, and alternatives with a qualified healthcare professional.